Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation.

We propose a numerical framework that permits an effective atlas-like representation of chemico-biological space based on a series of Cartesian planes mapping the ligands with the corresponding targets connected by an affinity parameter (K(i) or related). The numerical framework is derived from the concept of ligand efficiency indices, which provide a natural coordinate system combining the potency toward the target (biological space) with the physicochemical properties of the ligand (chemical space). This framework facilitates navigation in the multidimensional drug discovery space using map-like representations based on pairs of combined variables related to the efficiency of the ligands per Dalton (molecular weight or number of non-hydrogen atoms) and per unit of polar surface area (or number of polar atoms).

[1]  Richard Wynn,et al.  Structural Insights into the Design of Nonpeptidic Isothiazolidinone-containing Inhibitors of Protein-tyrosine Phosphatase 1B* , 2006, Journal of Biological Chemistry.

[2]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[3]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[4]  C. Abad-Zapatero,et al.  Ligand efficiency indices for effective drug discovery , 2007, Expert opinion on drug discovery.

[5]  Renxiao Wang,et al.  The PDBbind database: methodologies and updates. , 2005, Journal of medicinal chemistry.

[6]  E. Valeur,et al.  Discovery and structure-guided drug design of inhibitors of 11beta-hydroxysteroid-dehydrogenase type I based on a spiro-carboxamide scaffold. , 2009, Bioorganic & medicinal chemistry letters.

[7]  Marcel L Verdonk,et al.  Group Efficiency: A Guideline for Hits‐to‐Leads Chemistry , 2008, ChemMedChem.

[8]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[9]  Renxiao Wang,et al.  The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. , 2004, Journal of medicinal chemistry.

[10]  Dan C. Fara,et al.  Lead-like, drug-like or “Pub-like”: how different are they? , 2007, J. Comput. Aided Mol. Des..

[11]  X Chen,et al.  BindingDB: a web-accessible molecular recognition database. , 2001, Combinatorial chemistry & high throughput screening.

[12]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[13]  L. Iversen,et al.  2-(Oxalylamino)-Benzoic Acid Is a General, Competitive Inhibitor of Protein-tyrosine Phosphatases* , 2000, The Journal of Biological Chemistry.

[14]  Cele Abad-Zapatero,et al.  A sorcerer's apprentice and The Rule of Five: from rule-of-thumb to commandment and beyond. , 2007, Drug discovery today.

[15]  Vicki L. Nienaber,et al.  Discovering novel ligands for macromolecules using X-ray crystallographic screening , 2000, Nature Biotechnology.

[16]  Brett A Tounge,et al.  The role of molecular size in ligand efficiency. , 2007, Bioorganic & medicinal chemistry letters.

[17]  Ole Hvilsted Olsen,et al.  Structure-based Design of a Low Molecular Weight, Nonphosphorus, Nonpeptide, and Highly Selective Inhibitor of Protein-tyrosine Phosphatase 1B* , 2000, The Journal of Biological Chemistry.

[18]  P. Leeson,et al.  A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.

[19]  Michael G. Lerner,et al.  Binding MOAD (Mother Of All Databases) , 2005, Proteins.

[20]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[21]  Ian M. Eggleston,et al.  Structure-Based Dissection of the Natural Product Cyclopentapeptide Chitinase Inhibitor Argifin , 2008, Chemistry & biology.

[22]  Tudor I. Oprea,et al.  Chemography: the Art of Navigating in Chemical Space , 2000 .

[23]  Heather A Carlson,et al.  Exploring protein-ligand recognition with Binding MOAD. , 2006, Journal of molecular graphics & modelling.

[24]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[25]  E. Valeur,et al.  Discovery and structure-activity relationships of pentanedioic acid diamides as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type I. , 2009, Bioorganic & medicinal chemistry letters.

[26]  Thomas R Downs,et al.  1,2,3,4-Tetrahydroisoquinolinyl sulfamic acids as phosphatase PTP1B inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[27]  J. T. Metz,et al.  Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.

[28]  A. Hopkins,et al.  Navigating chemical space for biology and medicine , 2004, Nature.

[29]  Emanuele Perola,et al.  An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. , 2010, Journal of medicinal chemistry.

[30]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[31]  Ian A. Watson,et al.  Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.

[32]  I. Kuntz,et al.  The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  X Chen,et al.  The binding database: overview and user's guide. , 2001, Biopolymers.

[34]  K. Stewart,et al.  Drug Guru: a computer software program for drug design using medicinal chemistry rules. , 2006, Bioorganic & medicinal chemistry.

[35]  Gang Liu,et al.  Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. , 2003, Journal of the American Chemical Society.

[36]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[37]  P. Hajduk,et al.  Identification of a monoacid-based, cell permeable, selective inhibitor of protein tyrosine phosphatase 1B. , 2003, Bioorganic & medicinal chemistry letters.

[38]  C. Bayly,et al.  The structural basis for the selectivity of benzotriazole inhibitors of PTP1B. , 2003, Biochemistry.

[39]  Michael Bower,et al.  Structural Basis for Inhibition of Protein-tyrosine Phosphatase 1B by Isothiazolidinone Heterocyclic Phosphonate Mimetics* , 2006, Journal of Biological Chemistry.

[40]  S F Campbell,et al.  Science, art and drug discovery: a personal perspective. , 2000, Clinical science.

[41]  Zelda R. Wasserman,et al.  Structural basis for inhibition of protein-tyrosine phosphatase 1B by isothiazolidinone heterocyclic phosphonate mimetics. , 2006 .

[42]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..